Catalyst Pharmaceuticals, Inc. (CPRX)
NEUTRALFundamental
72
Preço
$-
Capitalização de Mercado
$3.85B
Parte 1 · Quanto vale a empresa
Visão Geral
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$597M
Últimos 12 meses (até 31/03/2026)
Resultado Líquido
$221M
Últimos 12 meses (até 31/03/2026)
Fluxo de Caixa Livre
$172M
Capital Próprio Total
$1.01B
Passivo Total
$3M
Rácio de Liquidez
7.10
Cobertura de Juros
-
Dívida/EBITDA
0.01
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$47.09
Preço Atual
-
Margem de Segurança
-
Intervalo de Valor Justo
$30.61 - $63.58
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
17.42
ROE
24.5%
Rácio P/B
3.80
P/FCF
-
Margem Bruta
86.0%
ROIC
20.8%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
20.8%
WACC
8.0%
ROIC − WACC
+12.8 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
Critérios de Análise Fundamental
Aprovado (16)
- ROIC 20.8%
- Gross Margin 86.0%
- Debt/Equity ratio
- Operating Margin 44.8%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 23.6%
- Revenue Growth 5Y 37.7%
- Earnings Surprise avg 13.8%
- PEG Ratio 0.92
- Earnings Quality (OCF/NI) 0.94
- Net Margin Trend 37.1% vs 36.9%
Reprovado (4)
- P/B Ratio 3.80
- DCF valuation (Unknown)
- Analyst Consensus 0% Buy
- Piotroski F-Score 1/9
Indisponível (7)
- EPS data insufficient
- Historical price data insufficient
- P/FCF NaN
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- Share Dilution (missing shares data)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Moderada: alguma diferença entre lucros e caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Patrick J. McEnany | Co-Founder & Non-Executive Chairman | 78 |
| Mr. Richard John Daly M.B.A. | President, CEO & Director | 64 |
| Mr. Michael W. Kalb CPA | Executive VP, Treasurer & CFO | 54 |
| Dr. Steven R. Miller Ph.D. | Executive VP, COO & Chief Scientific Officer | 63 |
| Mr. Jeffrey Del Carmen | Executive VP & Chief Commercial Officer | 54 |
| Dr. William T. Andrews FACP, M.D. | Chief Medical Officer | 60 |
| Ms. Mary Coleman | VP & Head of Investor Relations | - |
| Mr. Brian Elsbernd J.D. | Chief Compliance Officer & Chief Legal Officer | 61 |
| Mr. Gregg Russo | Chief Human Resources Officer | 62 |
| Dr. Preethi Sundaram Ph.D. | Chief Strategy Officer | 49 |
Risco de Auditoria
8
Risco do Conselho
3
Risco de Remuneração
8
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for CPRX, sourced from Markets Gazette.
- 4/27/2026POSITIVEItaly’s Angelini Said to Explore Acquisition of Catalyst Pharma
Catalyst Pharmaceuticals Inc. is reportedly being explored for acquisition by Italian drugmaker Angelini Pharma. This potential deal signals significant interest in Catalyst's assets and market position, suggesting a possible premium valuation for shareholders. Angelini Pharma's exploration indicates a strategic move to expand its global reach, potentially through acquiring Catalyst's product pipeline or market access. Investors will be watching for further developments, as an acquisition could lead to a substantial uplift in Catalyst's stock price.
- 4/27/2026NEUTRALItaly’s Angelini Said to Explore Catalyst Pharma Acquisition
Angelini Pharma, an Italian drugmaker, is reportedly exploring the acquisition of US-based Catalyst Pharmaceuticals Inc. This potential deal is part of Angelini's strategy to broaden its international presence. Catalyst Pharmaceuticals, trading on the Nasdaq, specializes in treatments for rare autoimmune diseases. While the exploration is in its early stages and no deal is guaranteed, the news highlights potential consolidation within the pharmaceutical sector. Investors will monitor developments for any concrete offers and the strategic rationale behind such a move.
via Markets Gazette